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ABSTRACT
Objective: The objective of this study was to compare renal function in diabetic 
hypertensive chronic kidney disease patients receiving enalapril or losartan.
Design: This was a retrospective analytic cohort study.
Setting:  Kenyatta National Hospital, Nairobi, Kenya. 
Subjects: Two hundred adult patients with hypertension and diabetic nephropathy. 
Interventions: One hundred and sixteen participants received an enalapril regimen 
while 84 were on a losartan regimen. 
Main outcome measures: time to doubling of serum creatinine and changes in the 
levels of proteinuria.
Results: There was a higher risk of doubling of serum creatinine with losartan (Adjusted 
HR=1.572; [95% CI:1.015-2.434]; p=0.043) than enalapril. There was a significant 
difference in time to doubling between the two arms – losartan 18 months, enalapril 
36 month (p=0.046). The changes in the levels of proteinuria between the two arms 
were not statistically significant for most of the follow up period except at the 15th 
month from treatment initiation (p=0.05).
Conclusions: Enalapril was found to be more reno-protective compared to losartan. 
Where feasible, we suggest local use of enalapril as opposed to losartan for diabetic 
hypertensive chronic kidney disease patients. 
INTRODUCTION
Chronic kidney disease (CKD) is an increasing 
health concern associated with adverse outcomes. 
Its prevalence is increasing at a rate of 8% per year 
worldwide (1). The etiology of CKD differs by region, 
age, gender and race. In Europe, Japan and the United 
States, diabetic nephropathy is the leading cause 
of CKD, while in the developing world, chronic 
glomerulonephritis and systemic hypertension are 
the leading causes (1).
 Renin Angiotensin Aldosterone System (RAAS) 
modifiers such as  Angiotensin Converting Enzyme 
(ACE) inhibitors and the Angiotensin Receptor 
Blockers (ARBs) are used to control blood pressure 
and also to retard the progression to end stage renal 
failure (2). Enalapril (an ACE inhibitor) and losartan 
(an ARB) are commonly used at the renal and diabetic 
clinics in Kenyatta National Hospital (KNH), the 
largest teaching and referring hospital in Kenya. 
 Reliable statistics for End Stage Renal Disease 
(ESRD) are lacking in African countries. It is however 
noted that CKD is at least three to four times more 
prevalent in Sub Saharan Africa than in more 
developed countries (3). In East and Central Africa, 
it is reported that there is poor response to treatment 
and faster progression to renal failure. 
 ACE inhibitors are useful in treating diabetic 
nephropathy since they reduce proteinuria and 
stabilize renal function which may be independent 
of blood pressure lowering. This benefit may be due 
to improved renal hemodynamics with decreased 
glomerular efferent arteriolar resistance and a drop 
in the intra-glomerular capillary pressure (4).
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ARBs block the angiotensin type 1 receptor (AT1). 
The incidence of cough with these drugs is very low 
compared to ACE inhibitors. They are also considered 
to offer a more complete inhibition of angiotensin 
action (4).
 More recently, direct renin inhibitors have been 
in use (Aliskerin®) and they block  the RAAS at its 
point of activation, resulting in reduced plasma renin 
activity and blood pressure lowering (5). There is 
not much long term data available on this class of 
drugs. Clinical trials are still ongoing to evaluate 
their usefulness (6).
 Local studies  have evaluated the adequacy of 
blood pressure control in patients with CKD and 
hypertension (7, 8). However, these studies neither 
investigated nor compared renal function in patients 
who were on either ACE inhibitors or ARBs. There 
is therefore a paucity of local data regarding the 
use of these drugs and the renal outcomes. Most 
studies comparing renal outcomes in patients using 
these drugs have been done in Europe, Asia and the 
United States with the inclusion of few black patients. 
Furthermore, there may be differences in how local 
populations respond to therapy to treatment by ACE 
inhibitors and ARBs compared to populations in 
Western and Asian countries.
 The aim of this study was to compare the effects 
of losartan and enalapril therapies on renal function in 
diabetic patients with hypertension. The time to and 
incidence of doubling of baseline serum creatinine 
levels as well as changes in levels of proteinuria were 
compared.
MATERIALS AND METHODS
Ethical approval was granted by the Kenyatta 
National Hospital Ethics and Research Committee 
(KNH-ERC/A/140) to carry out a retrospective 
analytic cohort study at the hospital’s renal and 
diabetic clinics. Patient files dating back seven years 
(January 2006-December 2012) were perused. Good 
Clinical Practice (GCP) guidelines were adhered 
to as outlined by the International Conference on 
Harmonization (ICH). Confidentiality of the patients’ 
medical records was maintained and no names 
were included during data collection. Patients were 
assigned study numbers in place of hospital patient 
identification numbers. A link log was created and 
kept under lock and key accessible only by the 
principal investigator. All original records pertaining 
to the study were also kept under lock and key 
accessible only by the investigators. 
 The target population for the study consisted of 
adult males and females ≥ 18 years of age diagnosed 
with diabetes, hypertension and CKD who were 
followed up at the KNH renal and diabetic clinic. 
Patients recruited had been on either losartan or 
enalapril therapies for a minimum period of twelve 
months continuously. Patients who were either on 
renal replacement therapy or had undergone a renal 
transplant or pregnant were excluded from the study. 
Universal sampling of all eligible files was then 
done. Data were abstracted using a designed data 
collection tool. 
 For data analysis and interpretation, chronic 
kidney disease was defined as the presence proteinuria 
and GFR of less than 60ml/min/1.73m2 over a 3 
month period or by clinician diagnosis. Proteinuria 
was defined by a positive dipstick urinalysis of > 1or + 
1. The doubling of the serum creatinine concentration 
was defined as the first serum creatinine value that 
was twice the baseline value. 
Outcomes of interest: The main outcomes of interest were 
doubling of baseline serum creatinine and changes in 
the level of proteinuria. The independent variables 
included age, gender, diabetes mellitus, hypertension, 
duration of illnesses, concurrent medications, smoking 
and alcohol habits, types of antihypertensives and 
patient adherence. Confounding variables included 
the use of nephrotoxic drugs, co-morbidities that 
may have caused renal failure and use of multiple 
antihypertensives. 
Data analysis: Descriptive data analysis was carried out 
on all variables. The mean and median were calculated 
as the measures of central tendency. The range and 
interquartile range (IQR) for continuous variables 
was reported. For all categorical variables, the 
proportionate composition and the 95% confidence 
interval were reported.
 Inferential tests such as the T- test, ANOVA and 
Chi Square were used to compare characteristics 
across the two arms. The 95% confidence interval for 
mean difference across the two independent groups 
was calculated. 
 Survival data analysis was done using the Kaplan 
Meier method. Time to doubling of baseline serum 
creatinine was compared across study arms using 
the Log rank test. Associations were measured by 
the determination of the hazard ratio (HR).
 Confounding was controlled for using the Cox 
regression models. Potential confounders were 
identified from the independent variables by a 
manned forward step wise modeling approach.  IBM 
SPSS version 20 was used for these analyses. P values 
below 0.05 were considered statistically significant 
for all analyses.
RESULTS
Study cohort: We sampled 920 patients with CKD, of 
whom 200 met the eligibility criteria.  Reasons for 
exclusions are shown in Figure 3.1.
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Figure 1
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Not hypertensive (n=116) 
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Not on either enalapril or losartan (n=107) 
Not on treatment for more than 12 months (n=18) 
Less than 18 years old (n=4) 
Patient on renal replacement therapy (n=140) 
Post renal transplant patients (n=2) 
CKD of other etiology other than hypertension and diabetes 
(n=260) 






Socio- demographic characteristics of the study population: 
The patient gender ratio was approximately 1:1 (Table 
1). Median age for all the patients was 63 years (range: 
18- 95 years). More than three quarters of the patients 
were above 50 years of age. Median age for patients 
who used enalapril regimen was 61 years (range: 51-70 
years). This was significantly lower compared to the 
age of patients who used losartan regimen (median 
age: 65 years, range: 57-71 years), (p=0.044). 
Medical history and baseline renal parameters of the study 
population: At diagnosis, 37.0% of the patients were at 
stage 3 of renal failure and a cumulative percentage 
of 33.5% were at stage 4 and 5 (Table 2). A greater 
proportion of the participants had been in renal 
failure for 3-4 years (34.5%). At diagnosis, the median 
baseline serum creatinine value was 165 µmol/L (IQR: 
105-277) while the baseline protein in urine was not 
detectable in 41% of the study population.  
Table 1
Socio-demographic characteristics of the study population







Gender; n (%)  
Female 101 (50.5) 58 (50.0) 43 (51.2) 0.868
Male 99 (49.5) 58 (50.0) 41 (48.8)
Age in years; Median (IQR) 63 (54 – 70) 61 (51 – 70) 65 (57 – 71) 0.044
<=50 years 33 (16.5) 25 (21.6) 8 (9.5) 0.024
>50 years 167 (83.5) 91 (78.4) 76 (90.5)
Marital status; n (%)
Single 21 (10.5) 17 (14.7) 4 (4.8) 0.067
Married 173 (86.5) 95 (81.9) 78 (92.9)
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Once married 6 (3.0) 4 (3.4) 2 (2.4)
Highest level of education; n (%)  
Informal 23 (11.5) 17 (14.7) 6 (7.1) 0.369
Primary level 80 (40.0) 43 (37.1) 37 (44.0)
Secondary level 73 (36.5) 43 (37.1) 30 (35.7)
Tertiary level 24 (12.0) 13 (11.2) 11 (13.1)
Use of alcohol; n (%)
Yes 19 (9.5) 15 (12.9) 4 (4.8) 0.052
No 181 (90.5) 101 (87.1) 80 (95.2)
Cigarette smoking; n (%)
Yes 16 (8.0) 11 (9.5) 5 (6.0) 0.364
No 184 (92.0) 105 (90.5) 79 (94.0)
Table 2








Type of diabetes; n (%)  
Type 1 19 (9.5) 16 (13.8) 3 (3.6) 0.015
Type 2 181 (90.5) 100 (86.2) 81 (96.4)
Duration of diabetes; n (%)
0-24 months 13 (6.5) 10 (8.6) 3 (3.6)
25-48 months 12 (6.0) 10 (8.6) 2 (2.4)
49-72 months 23 (11.5) 14 (12.1) 9 (10.7) 0.174
72-96 months 17 (8.5) 10 (8.6) 7 (8.3)
>96 months 135 (67.5) 72 (62.1) 63 (75.0)
Duration of hypertension; n (%)  
0-24 months 24 (12.0) 19 (16.4) 5 (6.0)
25-48 months 22 (11.0) 14 (12.1) 8 (9.5)
49-72 months 29 (14.5) 17 (14.7) 12 (14.3) 0.072
72-96 months 29 (14.5) 19 (16.4) 10 (11.9)
>96 months 96 (48.0) 47 (40.5) 49 (58.3)
Baseline Stage of renal failure; n (%)  
Stage1 18 (9.0) 8 (6.9) 10 (11.9)
Stage2 41 (20.5) 24 (20.7) 17 (20.2)
Stage3 74 (37.0) 44 (37.9) 30 (35.7) 0.584
Stage4 38 (19.0) 25 (21.6) 13 (15.5)
Stage5 29 (14.5) 15 (12.9) 14 (16.7)
Duration since diagnosis of renal failure (years); n (%) 
≥ 7 36 (18.0) 24 (20.7) 12 (14.3)
5-6 52 (26.0) 31 (26.7) 21 (25.0)
3-4 69 (34.5) 41 (35.3) 28 (33.3) 0.314
1-2 43 (21.5) 20 (17.2) 23 (27.4)
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Baseline Serum Creatinine in µmol/L; Median (IQR) 165 (105 – 
277)
171 (116 – 
277)
154 (100 – 
268)
0.550
Baseline proteinuria mg/dl; n (%)
<30 89 (44.5) 49 (42.2) 40 (47.6)
30 27 (13.5) 23 (19.8) 4 (4.8)
100 33 (16.5) 18 (15.5) 15 (17.9) 0.021
>=300 51 (25.5) 26 (22.4) 25 (29.8)
Protein; n (%)
Absent 82 (41.0) 47 (40.5)
Incidence of doubling of serum creatinine: Survival 
probability at first doubling in serum creatinine 
decreases from 1.000 to 0.240 in a span of 1 to 57 
months.  Median time to doubling of serum creatinine 
was 24 months.
 Survival probabilities were compared between 
different treatment arms. Figure 3.1 presents a 
comparison of survival probabilities to 1st doubling 
of Serum Creatinine between treatment arms. There 
was a significant difference in survival probabilities 
between the treatment arms (p=0.046).
Figure 2
Kaplan-Meir survival probability curve to first doubling of serum creatinine
Multivariate analysis: All factors identified to correlate 
with doubling of serum creatinine or use of enalapril 
or losartan at p<0.1 were considered. Fourteen factors 
that were considered as candidates for the analysis 
included: regimen, date started on regimen, age in 
years, marital status, use of alcohol, type of diabetes, 
duration of hypertension, baseline protein in urine, 
use of amlodipine, carvedilol,  cotrimoxazole, baseline 
stage of renal failure, baseline serum creatinine and 
baseline eGFR. Upon specifying backward conditional 
method with removal at p<0.05, twelve iterations were 
performed. The twelve successive iterations yielded 
to a parsimonious (reduced) model. Adjusting for 
baseline serum creatinine, the use of losartan was 
significantly associated with doubling in serum 
creatinine. It was established that a patient put on 
losartan regimen had 1.572-fold risk of experiencing 
doubling of serum creatinine levels compared to one 
on enalapril regimen(adjusted HR=1.572; 95% CI: 
[1.015,  2.434]; p=0.043).  
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Changes in the levels of proteinuria: Out of 200 study 
patients, 54 had complete data on the level of protein 
in urine for 15 months of follow-up. Stacked bar 
graphs were used to illustrate the changes in the 
proportions of patients at each level of proteinuria. 
A stacked bar graph for enalapril and losartan was 
plotted as shown in Figures 3 and 4, respectively. 
There was no significant difference in the distribution 
of patients with different categories of protein in 
urine by treatment arms at most time points except 
at month 15.
Figure 3
Changes in the proportion of patients at different levels of proteinuria with time in the enalapril arm
  
Figure 4
Changes in the proportion of patients at different levels of proteinuria with time in the losartan arm
Though the differences in the proportion of patients during follow up in the two arms were not statistically 
significant (month 0: p = 0.301, month 3: p=0.162, 
month 6: p = 0.245, month 9: p = 0.587, month 12: p 
= 0.556), comparisons between Figures 3 and 4 can be 
made. A significant difference was only noted at month 
15 of follow up (p=0.053). In both the losartan and 
enalapril arms, the proportion of patients with ≥300 
mg/dl of protein in urine decreased. The proportion 
of patients in the <30 mg/dl range of protein in urine 
increased in the losartan arm while a decrease was 
observed in the enalapril arm between baseline and 
month 15 of follow up. Enalapril appeared to have 
a greater protective effect with greater magnitude of 
reduction in the ≥300 mg/dl of protein in urine level.
DISCUSSION
Our results indicate that there is a statistically 
significant difference in the risk of doubling of serum 
creatinine between the two study arms. Patients 
on losartan had a 1.6 fold risk of experiencing a 
doubling of serum creatinine compared to those on 
enalapril. This risk is apparent after controlling for 
most confounders by the Cox regression model. The 
parsimonious model revealed that the baseline serum 
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creatinine concentration was predictive of doubling 
of the serum creatinine concentration. 
 Survival data analysis using Kaplan-Meir 
method revealed that the median time to the event 
was 24 months for both arms combined. However, 
a comparison of the two arms revealed that the 
losartan arm experienced this event at a median of 
16 months of follow up whereas in the enalapril arm 
the experience was at 36 months (p = 0.046). This 
suggests that enalapril was superior to losartan in 
terms of preservation of renal function.
 Our findings were not in agreement with the 
ONTARGET and DETAIL studies regarding the 
doubling of serum creatinine following treatment 
with ACE inhibitors or ARBs. The ONTARGET trial 
compared telmisartan and ramipril and concluded 
that the risk of doubling of serum creatinine was 
not statistically significant different between the 
two arms.(9) Conclusions from the DETAIL study 
group, a head to head comparison of telmisartan 
and enalapril were similar.(10)  Our findings indicate 
that patients on an ARB (losartan) were at a higher 
risk of doubling of serum creatinine than those on 
an ACEi (enalapril). This can be interpreted to mean 
that enalapril is more renoprotective than losartan. 
The ONTARGET and DETAIL studies were done in 
predominantly caucasian populations. Our study was 
done in a black population. Perhaps this may also 
account to some degree for the apparent variations 
of results between those studies and this study. 
Furthermore, the specific drugs used in this study 
were different.
 The changes in the levels of proteinuria did not 
differ across the enalapril and losartan arms for most 
of the follow up period till month 15 where it became 
significant (p=0.05). Patients on the enalapril based 
regimens had greater reductions in proteinuria at 
the ≥300mg/dl mark compared to those on losartan 
regimens. Our results concur with the argument that 
patients with higher levels of proteinuria above 1g 
per day at baseline or during follow up benefit most 
from therapy with ARBs or ACE inhibitors (9).
 The ONTARGET study during a comparison of 
the ACE inhibitor, ramipril and the ARB, telmisartan 
found that the decrease in urinary albumin excretion 
was less with telmisartan  compared to  with ramipril 
(9). Lacourciere et al. on the other hand compared 
reduction of urinary albumin excretion between 
losartan and enalapril. After 52 weeks of follow up, 
the reduction in proteinuria from baseline was higher 
with enalapril than with losartan .(11) Our study 
concurred with those findings, even though there were 
no statistically significant differences in the changes 
in the levels of proteinuria between the two arms for 
most of the follow up period except month 15. We 
suggest that our findings relating to changes in the 
level of proteinuria be interpreted with caution. 
 We postulate that the differential effects observed 
between the two drugs are related to their mechanisms 
of action. Both drugs not only block the RAAS, they 
also cause differential stimulation of the Kallikrein 
Kinin System (KKS) with the resultant renal effects.  (1, 
12, 13).  The beneficial effects of both ACE inhibitors 
and ARBs can be attributed in part to activation 
of the KKS. This may be mediated by enhanced 
synthesis of nitric oxice (NO) and prostacylin, a 
prostaglandin (PG), which shifts the metabolism 
from mitochondrial respiration to glycolysis. NO 
and PG cause vasodilatation, prevent fibrosis and 
inflammation, reduce production of ROS and are anti-
thrombotic. All these effects prevent the progression 
of diabetic nephropathy. Of the two classes of drugs, 
ACE inhibitors are more effective in enhancing the 
activity of the KKS (14). It has been argued that even 
though ACE inhibitors were developed as RAAS 
blockers, they function primarily as stimulators of 
the kinins rather than ACE inhibitors (14, 15). This 
argument would support our findings where patients 
on enalapril regimens had better preserved renal 
function compared to those on losartan regimens. 
Information is, however, lacking on the role of kinins 
on the intrarenal effects of ACE inhibitors and ARBs. 
Animal studies have demonstrated that kinins may 
cause efferent arteriolar vasodilatation, but this effect 
has not been demonstrated in humans putting doubt 
on the role of their role in reduction of proteinuria.
(14) 
 A limitation of the present study, as is common 
with retrospective studies, is missing information, 
which eventually reduced the sample size thereby 
lowering the power of our study from 90% to 86%. 
The small sample size also may have contributed to 
the lack of statistically significant differences in the 
changes in the levels of proteinuria between the two 
arms.  The variation of data on proteinuria which 
was largely due to the fact that most patients did not 
have the urinalysis test done regularly as requested 
by the physician may also have affected our results. 
Finally, this being a retrospective study also limited 
our ability to collect data on other key factors that 
may have contributed to the observed differences 
such as ethnicity and genetic polymorphisms. 
CONCLUSION 
The results show that patients who were on losartan 
based regimens were at a higher risk of experiencing 
a doubling of serum creatinine than those on enalapril 
based regimens. 
 We therefore recommend the use of enalapril 
based regimens as first line therapy in type 2 
diabetic CKD patients with hypertension. The use of 
losartan as first line in RAAS blockade naïve patients 
should be discouraged based on the higher risk of 
decreased renal function. Prospective cohort studies 
or randomised controlled trials with larger sample 
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sizes are necessary in order to provide more evidence 
of the superior effects of ACE inhibitors especially in 
black populations.
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